» Articles » PMID: 28784597

Modulating NAD Metabolism, from Bench To bedside

Overview
Journal EMBO J
Date 2017 Aug 9
PMID 28784597
Citations 106
Authors
Affiliations
Soon will be listed here.
Abstract

Discovered in the beginning of the 20 century, nicotinamide adenine dinucleotide (NAD) has evolved from a simple oxidoreductase cofactor to being an essential cosubstrate for a wide range of regulatory proteins that include the sirtuin family of NAD-dependent protein deacylases, widely recognized regulators of metabolic function and longevity. Altered NAD metabolism is associated with aging and many pathological conditions, such as metabolic diseases and disorders of the muscular and neuronal systems. Conversely, increased NAD levels have shown to be beneficial in a broad spectrum of diseases. Here, we review the fundamental aspects of NAD biochemistry and metabolism and discuss how boosting NAD content can help ameliorate mitochondrial homeostasis and as such improve healthspan and lifespan.

Citing Articles

Peroxisome proliferator-activated receptor γ coactivator 1α maintains NAD bioavailability protecting against steatohepatitis.

Shen W, Wan X, Hou J, Liu Z, Mao G, Xu X Life Med. 2025; 1(2):207-220.

PMID: 39871927 PMC: 11749270. DOI: 10.1093/lifemedi/lnac031.


Sex-specific mechanisms in vascular aging: exploring cellular and molecular pathways in the pathogenesis of age-related cardiovascular and cerebrovascular diseases.

Ungvari A, Gulej R, Patai R, Papp Z, Toth A, Szabo A Geroscience. 2025; 47(1):301-337.

PMID: 39754010 PMC: 11872871. DOI: 10.1007/s11357-024-01489-2.


Potential Therapeutic Interventions Targeting NAD Metabolism for ALS.

Lundt S, Ding S Cells. 2024; 13(17.

PMID: 39273079 PMC: 11394323. DOI: 10.3390/cells13171509.


Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials.

Wen J, Syed B, Kim S, Shehabat M, Ansari U, Razick D Cureus. 2024; 16(8):e65961.

PMID: 39221308 PMC: 11365583. DOI: 10.7759/cureus.65961.


Nicotinamide riboside restores nicotinamide adenine dinucleotide levels and alleviates brain injury by inhibiting oxidative stress and neuroinflammation in a mouse model of intracerebral hemorrhage.

She J, Zhang H, Xu H, Li Y, Wu J, Han R Mol Neurobiol. 2024; 62(2):1321-1336.

PMID: 38981960 PMC: 11772386. DOI: 10.1007/s12035-024-04335-w.


References
1.
Camacho-Pereira J, Tarrago M, Chini C, Nin V, Escande C, Warner G . CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016; 23(6):1127-1139. PMC: 4911708. DOI: 10.1016/j.cmet.2016.05.006. View

2.
Yin T, Britt J, De Jesus-Cortes H, Lu Y, Genova R, Khan M . P7C3 neuroprotective chemicals block axonal degeneration and preserve function after traumatic brain injury. Cell Rep. 2014; 8(6):1731-1740. PMC: 4206693. DOI: 10.1016/j.celrep.2014.08.030. View

3.
Escande C, Nin V, Price N, Capellini V, Gomes A, Barbosa M . Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes. 2012; 62(4):1084-93. PMC: 3609577. DOI: 10.2337/db12-1139. View

4.
Klaidman L, Morales M, Kem S, Yang J, Chang M, Adams Jr J . Nicotinamide offers multiple protective mechanisms in stroke as a precursor for NAD+, as a PARP inhibitor and by partial restoration of mitochondrial function. Pharmacology. 2003; 69(3):150-7. DOI: 10.1159/000072668. View

5.
Wojcik M, Seidle H, Bieganowski P, Brenner C . Glutamine-dependent NAD+ synthetase. How a two-domain, three-substrate enzyme avoids waste. J Biol Chem. 2006; 281(44):33395-402. DOI: 10.1074/jbc.M607111200. View